bioAffinity Technologies, Inc.

AI-generated fair value estimate for this company.

Method: 10-year revenue-growth-to-profitability DCF: $5.90M TTM revenue base; revenue growth 40%/35%/30%/25%/20% years 1-5, then 15%/12%/10%/8%/6% years 6-10; FCF margin improving from -90% in year 1 through breakeven around year 4 to 20% by year 10 as CyPath Lung test volumes scale against largely fixed lab and overhead costs; 22% discount rate (pre-profitability, dilution/going-concern risk); 3% terminal growth; plus $2.43M cash added as net cash; approximately 540K shares outstanding post reverse split.

Reasoning: BIAF has real, fast-growing test volume but is deeply loss-making with thin cash relative to its burn rate, so a DCF that only turns FCF-positive once volume scale is reached, plus adding current cash, better captures its risk/reward than an earnings multiple on negative earnings.